<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02916810</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00070464</org_study_id>
    <nct_id>NCT02916810</nct_id>
  </id_info>
  <brief_title>TMS for Symptom Reduction in Schizophrenia</brief_title>
  <official_title>TMS for Symptom Reduction in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the hypothesis that functionally navigated repetitive TMS stimulations to the&#xD;
      prefrontal cortex (PFC) modulate aberrant cortical electrical activities at PFC circuitry.&#xD;
      The TMS location of the PFC site will be individually localized by the symptom-related&#xD;
      functional connectivity between PFC and symptom related areas (such as the auditory and&#xD;
      language processing cortex). The investigators predict that such modulation will correct&#xD;
      abnormal activities in patients with schizophrenia, reduce symptoms, especially auditory&#xD;
      hallucination, and improve working memory/sustained attention performance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuroimaging studies suggest that aberrant activities at specific brain regions such as&#xD;
      sensory areas and language-related areas are related to psychosis symptoms including auditory&#xD;
      and visual hallucination, delusion, and thought disorders. Transcranial magnetic stimulation&#xD;
      (TMS) provides a non-invasive means for altering brain electrical neural activity. TMS has&#xD;
      been approved by FDA for treatment of depression. Other applications have not been approved&#xD;
      but it has been used in a wide range of clinical research especially in neurology and&#xD;
      psychiatry. Among psychotic symptoms, there are preliminary significant improvement in&#xD;
      treatments of auditory hallucination using TMS with small samples, but those treatments are&#xD;
      not robust in larger samples. The high inter-subject variability limits the efficacy of TMS&#xD;
      treatment in schizophrenia patients. The investigators aim to develop a TMS treatment method&#xD;
      with a fMRI-defined treatment target area, where the TMS target is individually identified to&#xD;
      maximize the TMS effects. The identification method uses both the anatomical character and&#xD;
      its functional relationship with auditory hallucination and other psychosis symptoms. If the&#xD;
      current target-identification successfully identified effective TMS target individually, the&#xD;
      treatment efficacy will be significant improved and more patients will benefit from TMS&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician's Questionnaire for Auditory Hallucinations (CQAH) is used to evaluate the treatment effect of rTMS on auditory hallucination in schizophrenia.</measure>
    <time_frame>4 weeks</time_frame>
    <description>The study will test whether the rTMS stimulations reduce auditory hallucination of schizophrenia after the last rTMS treatment session. The CQAH will be used by an clinician to evaluate the auditory hallucination severity of schizophrenia patients before and after the rTMS series.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electroencephalogram (EEG) is used to evaluate the brain electrical activities that are corresponding to the treatment effect on auditory hallucination.</measure>
    <time_frame>4 weeks</time_frame>
    <description>The EEG recordings will be done before and after the rTMS series.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional magnetic resonance imaging (fMRI) is used to evaluate the brain activities that are corresponding to the treatment effect on auditory hallucination.</measure>
    <time_frame>4 weeks</time_frame>
    <description>The fMRI scans will be done before and after the rTMS series.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Schizophrenia and Related Disorders</condition>
  <arm_group>
    <arm_group_label>Active rTMS stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Real active rTMS stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham repetitive TMS stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active rTMS stimulation</intervention_name>
    <description>Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.</description>
    <arm_group_label>Active rTMS stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham rTMS stimulation</intervention_name>
    <description>Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.</description>
    <arm_group_label>Sham rTMS stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and Female between ages 21-62&#xD;
&#xD;
          -  Ability to give written informed consent (age 21 or above)&#xD;
&#xD;
          -  For patient participants, Evaluation to Sign Consent (ESC) 10 or greater.&#xD;
&#xD;
          -  Medication stability for 4 weeks (same drugs at same dosages)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of seizures&#xD;
&#xD;
          -  Any Family history of epilepsy in first degree relatives&#xD;
&#xD;
          -  Significant alcohol or other drug use (substance dependence within 6 months or&#xD;
             substance abuse within 1 month) other than nicotine or marijuana dependence.&#xD;
&#xD;
          -  Any major medical illnesses that may affect normal brain functioning. Examples of&#xD;
             these conditions include, but not limited to, stroke, CNS infection or tumor, other&#xD;
             significant brain neurological conditions.&#xD;
&#xD;
          -  Taking &gt; 400 mg clozapine/day&#xD;
&#xD;
          -  Failed TMS screening questionnaire&#xD;
&#xD;
          -  Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable&#xD;
             cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators,&#xD;
             cochlear implants, or electrodes) or any other metal object within or near the head,&#xD;
             excluding the mouth,that cannot be safely removed.&#xD;
&#xD;
          -  History of head injury with loss of consciousness over 10 minutes; history of brain&#xD;
             surgery&#xD;
&#xD;
          -  Can not refrain from using alcohol and/or marijuana 24 hours or more &amp; cigarette&#xD;
             smoking half and hour or more prior to experiments.&#xD;
&#xD;
          -  Woman who is pregnant (child-bearing potential but not on contraceptive and missing&#xD;
             menstrual period; or by self report; or by positive pregnancy test)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>62 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>L E Hong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoming Du, PhD</last_name>
    <phone>410-402-6036</phone>
    <email>xdu@mprc.umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dawn Detamore</last_name>
    <phone>410-402-6820</phone>
    <email>ddetamor@mprc.umaryland.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoming Du, PhD</last_name>
      <phone>410-402-6036</phone>
      <email>xdu@mprc.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dawn Detamore</last_name>
      <phone>410-402-6820</phone>
      <email>ddetamor@mprc.umaryland.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>September 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>L. Elliot Hong</investigator_full_name>
    <investigator_title>Professsor</investigator_title>
  </responsible_party>
  <keyword>transcranial magnetic stimulation</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

